TY  - JOUR
A1  - Ziegler, Alice
A1  - Meyer, Hanna
A1  - Otte, Insa
A1  - Peters, Marcell K.
A1  - Appelhans, Tim
A1  - Behler, Christina
A1  - Böhning-Gaese, Katrin
A1  - Classen, Alice
A1  - Detsch, Florian
A1  - Deckert, Jürgen
A1  - Eardley, Connal D.
A1  - Ferger, Stefan W.
A1  - Fischer, Markus
A1  - Gebert, Friederike
A1  - Haas, Michael
A1  - Helbig-Bonitz, Maria
A1  - Hemp, Andreas
A1  - Hemp, Claudia
A1  - Kakengi, Victor
A1  - Mayr, Antonia V.
A1  - Ngereza, Christine
A1  - Reudenbach, Christoph
A1  - Röder, Juliane
A1  - Rutten, Gemma
A1  - Schellenberger Costa, David
A1  - Schleuning, Matthias
A1  - Ssymank, Axel
A1  - Steffan-Dewenter, Ingolf
A1  - Tardanico, Joseph
A1  - Tschapka, Marco
A1  - Vollstädt, Maximilian G. R.
A1  - Wöllauer, Stephan
A1  - Zhang, Jie
A1  - Brandl, Roland
A1  - Nauss, Thomas
T1  - Potential of airborne LiDAR derived vegetation structure for the prediction of animal species richness at Mount Kilimanjaro
JF  - Remote Sensing
N2  - The monitoring of species and functional diversity is of increasing relevance for the development of strategies for the conservation and management of biodiversity. Therefore, reliable estimates of the performance of monitoring techniques across taxa become important. Using a unique dataset, this study investigates the potential of airborne LiDAR-derived variables characterizing vegetation structure as predictors for animal species richness at the southern slopes of Mount Kilimanjaro. To disentangle the structural LiDAR information from co-factors related to elevational vegetation zones, LiDAR-based models were compared to the predictive power of elevation models. 17 taxa and 4 feeding guilds were modeled and the standardized study design allowed for a comparison across the assemblages. Results show that most taxa (14) and feeding guilds (3) can be predicted best by elevation with normalized RMSE values but only for three of those taxa and two of those feeding guilds the difference to other models is significant. Generally, modeling performances between different models vary only slightly for each assemblage. For the remaining, structural information at most showed little additional contribution to the performance. In summary, LiDAR observations can be used for animal species prediction. However, the effort and cost of aerial surveys are not always in proportion with the prediction quality, especially when the species distribution follows zonal patterns, and elevation information yields similar results.
KW  - biodiversity
KW  - species richness
KW  - LiDAR
KW  - elevation
KW  - partial least square regression
KW  - arthropods
KW  - birds
KW  - bats
KW  - predictive modeling
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262251
SN  - 2072-4292
VL  - 14
IS  - 3
ER  - 
TY  - JOUR
A1  - Grünwald, Viktor
A1  - Pink, Daniel
A1  - Egerer, Gerlinde
A1  - Schalk, Enrico
A1  - Augustin, Marinela
A1  - Deinzer, Christoph K. W.
A1  - Kob, Viola
A1  - Reichert, Dietmar
A1  - Kebenko, Maxim
A1  - Brandl, Stephan
A1  - Hahn, Dennis
A1  - Lindner, Lars H.
A1  - Hoiczyk, Mathias
A1  - Ringsdorf, Uta
A1  - Hanker, Lars C.
A1  - Hempel, Dirk
A1  - De Rivas, Beatriz
A1  - Wismann, Tobias
A1  - Ivanyi, Philipp
T1  - Trabectedin for patients with advanced soft tissue sarcoma: a non-interventional, prospective, multicenter, phase IV trial
JF  - Cancers
N2  - This non-interventional, prospective phase IV trial evaluated trabectedin in patients with soft tissue sarcoma (STS) in real-life clinical practice across Germany. The primary endpoints were progression-free survival (PFS) rates at 3 and 6 months, as defined by investigators. Overall, 128 patients from 19 German sites were evaluated for efficacy and 130 for safety. Median age was 58.5 years (range: 23–84) and leiomyosarcoma was the most frequent histotype (n = 45; 35.2%). Trabectedin was mostly used as second/third-line treatment (n = 91; 71.1%). Median PFS was 5.2 months (95% CI: 3.3–6.7), with 60.7% and 44.5% of patients free from progression at 3 and 6 months, respectively. Median overall survival was 15.2 months (95% CI: 9.6–21.4). One patient achieved a complete and 14 patients a partial response, conferring an objective response rate of 11.7%. Decreases in white blood cells (27.0% of patients), platelets (16.2%) and neutrophils (13.1%) and increased alanine aminotransferase (10.8%) were the most common trabectedin-related grade 3/4 adverse drug reactions. Two deaths due to pneumonia and sepsis were considered trabectedin-related. Trabectedin confers clinically meaningful activity in patients with multiple STS histotypes, comparable to that previously observed in clinical trials and other non-interventional studies, and with a manageable safety profile.
KW  - trabectedin
KW  - STS
KW  - sarcoma
KW  - non-interventional
KW  - prospective
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-290898
SN  - 2072-6694
VL  - 14
IS  - 21
ER  -